Marco Faustini-Fustini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marco Faustini-Fustini has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ernesto Pasquini
ENT Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
4 shared publications - Giorgio Frank
Department of Neurosurgery, Center of Surgery for Pituitary Tumors and Endoscopic Skull Base Surgery, Bologna, Italy
4 shared publications Giovanna Elmi
Unità di Medicina Interna, Dipartimento Medico Ospedale Bellaria, Azienda USL di Bologna, Italy
4 shared publications- Matteo Zoli
Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy
4 shared publications Stefania Zaccaroni
Unità di Medicina Interna, Dipartimento Medico Ospedale Bellaria, Azienda USL di Bologna, Italy
4 shared publicationsAdelaide Valluzzi
3 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Operative Neurosurgery
The Modified Sparing Binostril Endoscopic Endonasal Approach Combined With an Algorithm-Based Reconstruction Strategy: Surgical and Functional Outcomes in Sellar and Suprasellar Lesions
BACKGROUND AND OBJECTIVES: Conventional binostril endoscopic endonasal approaches (EEAs) provide optimal surgical ergonomics but are often associated with sinonasal morbidity. Conversely, mononostril approaches preserve mucosal integrity at the expense of surgical maneuverability. We hypothesized that the modified sparing binostril approach (moSBA) may provide a favorable balance between surgical exposure, ergonomics, and sinonasal preservation while maintaining flexibility for risk-adapted reconstruction. This study evaluates the feasibility and functional outcomes of this technique combined with a risk-adapted skull base reconstruction strategy. METHODS: We retrospectively reviewed 81 patients who underwent EEA or extended EEA for sellar and suprasellar lesions between 2021 and 2025. All procedures were performed combining a paraseptal and a contralateral endonasal corridor (moSBA). The risk-adapted reconstructive algorithm included type 1 (hemostatic material with free mucosal graft), type 2 (inlay fat graft with onlay nasoseptal flap), and type 3 (modified gasket-seal). Outcomes included extent of resection, complications, and 22-item Sinonasal Outcome Test (SNOT-22) assessment. RESULTS: EEAs were performed in 56 (69.1%) and extended EEAs in 25 (30.9%) patients. Intraoperative cerebrospinal fluid (CSF) leakage occurred in 48 cases (59.3%) and was graded as 1 in 12.3%, 2 in 34.6%, and 3 in 12.3%. Reconstruction types 1, 2, and 3 were used in 40.7%, 46.9%, and 12.4% of cases, respectively. Gross total resection was achieved in 72.9%. Postoperative CSF leakage occurred in 2.5%. On exploratory multivariate analysis, reconstruction complexity was independently associated with higher postoperative SNOT-22 score (B = 3.379, 95% CI: 0.827-5.930, P = .010). CONCLUSION: The moSBA appears to be a feasible and safe option for selected sellar and suprasellar lesions, providing favorable surgical and functional outcomes in this single-center experience. Although higher reconstruction complexity was independently associated with higher postoperative SNOT-22 scores, residual confounding related to surgical invasiveness, skull base defect magnitude, and intraoperative CSF leakage severity cannot be excluded.
- 6 October 2026
- Published by Wolters Kluwer Health in Operative Neurosurgery
The Modified Sparing Binostril Endoscopic Endonasal Approach Combined With an Algorithm-Based Reconstruction Strategy: Surgical and Functional Outcomes in Sellar and Suprasellar Lesions
BACKGROUND AND OBJECTIVES: Conventional binostril endoscopic endonasal approaches (EEAs) provide optimal surgical ergonomics but are often associated with sinonasal morbidity. Conversely, mononostril approaches preserve mucosal integrity at the expense of surgical maneuverability. We hypothesized that the modified sparing binostril approach (moSBA) may provide a favorable balance between surgical exposure, ergonomics, and sinonasal preservation while maintaining flexibility for risk-adapted reconstruction. This study evaluates the feasibility and functional outcomes of this technique combined with a risk-adapted skull base reconstruction strategy. METHODS: We retrospectively reviewed 81 patients who underwent EEA or extended EEA for sellar and suprasellar lesions between 2021 and 2025. All procedures were performed combining a paraseptal and a contralateral endonasal corridor (moSBA). The risk-adapted reconstructive algorithm included type 1 (hemostatic material with free mucosal graft), type 2 (inlay fat graft with onlay nasoseptal flap), and type 3 (modified gasket-seal). Outcomes included extent of resection, complications, and 22-item Sinonasal Outcome Test (SNOT-22) assessment. RESULTS: EEAs were performed in 56 (69.1%) and extended EEAs in 25 (30.9%) patients. Intraoperative cerebrospinal fluid (CSF) leakage occurred in 48 cases (59.3%) and was graded as 1 in 12.3%, 2 in 34.6%, and 3 in 12.3%. Reconstruction types 1, 2, and 3 were used in 40.7%, 46.9%, and 12.4% of cases, respectively. Gross total resection was achieved in 72.9%. Postoperative CSF leakage occurred in 2.5%. On exploratory multivariate analysis, reconstruction complexity was independently associated with higher postoperative SNOT-22 score (B = 3.379, 95% CI: 0.827-5.930, P = .010). CONCLUSION: The moSBA appears to be a feasible and safe option for selected sellar and suprasellar lesions, providing favorable surgical and functional outcomes in this single-center experience. Although higher reconstruction complexity was independently associated with higher postoperative SNOT-22 scores, residual confounding related to surgical invasiveness, skull base defect magnitude, and intraoperative CSF leakage severity cannot be excluded.
- 4 August 2016
- Published by Springer Nature in Endocrine
- Vol. 56 (2) , 286-297
The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3
The spectrum of corticotroph cell adenomas is very wide. Though rarely, silent corticotroph cell adenomas (SCA) may transform into corticotroph cell adenomas associated with Cushing’s disease (CD). The aim of the study was to investigate the role of prohormone convertase 1/3 (PC1/3) in the transformation of SCA into CD. We reviewed the records of 1259 consecutive endoscopic endonasal procedures for pituitary adenomas from 1998 to 2013. Of these, 132 were CD and 44 were SCA. During the follow-up, three patients with SCA showed a clear transformation from SCA into CD and underwent surgery once again to remove the recurrent tumour. The PC1/3 expression was analysed by both immunohistochemistry and quantitative real time-polymerase chain reaction (qRT-PCR) in primary and recurrent tumours. The immunohistochemical PC1/3 expression was negative or weak in the three patients in the initial phase of SCA, while a strong expression was observed in the majority of neoplastic cells in tissue specimens obtained from the same three patients at the time of recurrence as CD. The immunohistochemical PC1/3 expression showed a strict correlation with the PC1/3 levels obtained by qRT-PCR. In 14 cases of SCA with no change of phenotype during the follow-up, the immunohistochemical PC1/3 expression was low and strictly associated with the level of PC1/3 obtained by qRT-PCR both in primary (14/14 cases) and in recurrent tumours (4/4 cases). Our study provides insight into the crucial role of the PC1/3 protein in the transformation of phenotype from SCA to CD.
- 4 August 2016
- Published by Springer Nature in Endocrine
- Vol. 56 (2) , 286-297
The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3
The spectrum of corticotroph cell adenomas is very wide. Though rarely, silent corticotroph cell adenomas (SCA) may transform into corticotroph cell adenomas associated with Cushing’s disease (CD). The aim of the study was to investigate the role of prohormone convertase 1/3 (PC1/3) in the transformation of SCA into CD. We reviewed the records of 1259 consecutive endoscopic endonasal procedures for pituitary adenomas from 1998 to 2013. Of these, 132 were CD and 44 were SCA. During the follow-up, three patients with SCA showed a clear transformation from SCA into CD and underwent surgery once again to remove the recurrent tumour. The PC1/3 expression was analysed by both immunohistochemistry and quantitative real time-polymerase chain reaction (qRT-PCR) in primary and recurrent tumours. The immunohistochemical PC1/3 expression was negative or weak in the three patients in the initial phase of SCA, while a strong expression was observed in the majority of neoplastic cells in tissue specimens obtained from the same three patients at the time of recurrence as CD. The immunohistochemical PC1/3 expression showed a strict correlation with the PC1/3 levels obtained by qRT-PCR. In 14 cases of SCA with no change of phenotype during the follow-up, the immunohistochemical PC1/3 expression was low and strictly associated with the level of PC1/3 obtained by qRT-PCR both in primary (14/14 cases) and in recurrent tumours (4/4 cases). Our study provides insight into the crucial role of the PC1/3 protein in the transformation of phenotype from SCA to CD.
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A107
Endoscopic Endonasal Treatment of Pituitary Adenomas Invading the Cavernous Sinus: Surgical Outcome in 374 Patients
Introduction: The advent of endoscopic endonasal technique has given a new horizon to cavernous sinus (CS) surgery. Indeed, the preliminary results reported by multiple authors along the last decade have revealed to be encouraging, showing a satisfactory tumor removal rate, endocrinological remission, and low morbidity. After 15 years of experience, we reviewed our surgical series of CS invading pituitary adenomas (PTA) to analyze the outcome of this approach in a larger surgical series with a more relevant follow-up. Patients and Methods: All consecutive patients with PTA involving the CS operated in our center from 1998 to 2013 were collected. All patients underwent preoperative baseline biohumoral assessments, visual field and acuity measurements, neurological examinations, and MRI. These examinations were repeated 3 months after surgery and then every 6 or 12 months to assess the neuroradiological and clinical outcome. During surgery, the effective intraoperative CS invasion (ICSI) was evaluated. At last follow-up, the surgical and endocrinological results were analyzed to assess the comprehensive evaluation as remission, control or no control of the tumor. Statistical analysis was performed to analyze the association between the CS invasion and comprehensive evaluation. Results: The series includes 374 patients (32% of at the entire series of PTA), underwent 393 surgical procedures, consisting in 314 midline transsphenoidal approach and 75 ethmoid-pterygo-sphenoidal approaches. The former was performed for PTA invading the medial and/or the superoinferior compartments of CS, while the latter was indicated for cases invading the anteroinferior and/or lateral compartment. Radical tumor removal was obtained in 248 cases (66.3%). Surgery permitted to achieve a complete endocrinological and tumor remission in 231 (61.8%) patients and allowed to obtain its control by other therapies in 128 cases (34.8%). Morbidity rate was of 6.6%, and the vast majority of complications resulted without any permanent sequelae. Permanent CN palsy was observed in only two cases (0.4%). At statistical analysis, the primary surgery, the lower Knosp, and ICSI scores confirmed to be associated with a more radical tumor removal (p = 0.007 and p = 0.001) and better comprehensive evaluation (p = 0.005 and p = 0.001).
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A107
Endoscopic Endonasal Treatment of Pituitary Adenomas Invading the Cavernous Sinus: Surgical Outcome in 374 Patients
Introduction: The advent of endoscopic endonasal technique has given a new horizon to cavernous sinus (CS) surgery. Indeed, the preliminary results reported by multiple authors along the last decade have revealed to be encouraging, showing a satisfactory tumor removal rate, endocrinological remission, and low morbidity. After 15 years of experience, we reviewed our surgical series of CS invading pituitary adenomas (PTA) to analyze the outcome of this approach in a larger surgical series with a more relevant follow-up. Patients and Methods: All consecutive patients with PTA involving the CS operated in our center from 1998 to 2013 were collected. All patients underwent preoperative baseline biohumoral assessments, visual field and acuity measurements, neurological examinations, and MRI. These examinations were repeated 3 months after surgery and then every 6 or 12 months to assess the neuroradiological and clinical outcome. During surgery, the effective intraoperative CS invasion (ICSI) was evaluated. At last follow-up, the surgical and endocrinological results were analyzed to assess the comprehensive evaluation as remission, control or no control of the tumor. Statistical analysis was performed to analyze the association between the CS invasion and comprehensive evaluation. Results: The series includes 374 patients (32% of at the entire series of PTA), underwent 393 surgical procedures, consisting in 314 midline transsphenoidal approach and 75 ethmoid-pterygo-sphenoidal approaches. The former was performed for PTA invading the medial and/or the superoinferior compartments of CS, while the latter was indicated for cases invading the anteroinferior and/or lateral compartment. Radical tumor removal was obtained in 248 cases (66.3%). Surgery permitted to achieve a complete endocrinological and tumor remission in 231 (61.8%) patients and allowed to obtain its control by other therapies in 128 cases (34.8%). Morbidity rate was of 6.6%, and the vast majority of complications resulted without any permanent sequelae. Permanent CN palsy was observed in only two cases (0.4%). At statistical analysis, the primary surgery, the lower Knosp, and ICSI scores confirmed to be associated with a more radical tumor removal (p = 0.007 and p = 0.001) and better comprehensive evaluation (p = 0.005 and p = 0.001).
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A070
Transsphenoidal Approach for Pituitary Metastases
Introduction: Pituitary metastases usually occur in advances stages of malignant diseases and sometimes as isolated secondary lesions. They present often with a specific clinical symptom and also the neuroradiological imaging could be evocative; however, their diagnosis is purely presumptive without histopathological confirmation. The aim of this study is to enlighten the results and limits of transsphenoidal surgery for these tumors. Materials and Results: In our center, 18 pituitary metastases have been operated through a transsphenoidal approach from 1992 till today. Overall, 17 patients complained of visual impairment, 8 of headache, 4 of ophthalmoplegia, while endocrine disturbances were present in 8 patients manifesting as DI, and in 7 patients as anterior hypopituitarism. At follow-up visual deficits improved in 12 cases, headache resolved in 5, and ophthalmoplegia regressed in 2 cases. No improvement of the endocrinological function was observed. The mean survival was of 11.8 months (range, 3–43 months), three patients are still alive after 3.6 and 33 months, respectively, since the surgery. Conclusion: The diagnosis of a pituitary metastasis can be done only by histological examinations. In some cases, some clinical signs, such as DI and ophthalmoplegia, which are rarely present in benign sellar tumors, can orientate the suspect toward this diagnosis. Also, neuroimaging can be sometimes relevant, showing infiltrating, irregular tumors with thickening of the pituitary stalk. We observed two scenarios. In the first, all these clinical and neuroradiological signs were not present, and no malignant disease was known, thus the diagnosis of metastatic lesion could be unexpected during the surgery. In these cases, surgery permitted to obtain a diagnosis and to orientate the following oncologic stadiation. In the second, this diagnosis was suspected before surgery, but this has been considered indicated with the goal to improve or control the heavy and progressive debilitating symptoms of the patients, such as the visual worsening. Because the poor prognosis observed in the series, we conclude that surgery should be performed only in the presence of symptoms affecting the QOL, or in the absence of a systemic known malignant disease. The endoscopic transsphenoidal approach represents a minimally invasive approach and should be preferred in such compromised patients. The surgery resulted effective on the quality of life, but not on its expectancy.
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A070
Transsphenoidal Approach for Pituitary Metastases
Introduction: Pituitary metastases usually occur in advances stages of malignant diseases and sometimes as isolated secondary lesions. They present often with a specific clinical symptom and also the neuroradiological imaging could be evocative; however, their diagnosis is purely presumptive without histopathological confirmation. The aim of this study is to enlighten the results and limits of transsphenoidal surgery for these tumors. Materials and Results: In our center, 18 pituitary metastases have been operated through a transsphenoidal approach from 1992 till today. Overall, 17 patients complained of visual impairment, 8 of headache, 4 of ophthalmoplegia, while endocrine disturbances were present in 8 patients manifesting as DI, and in 7 patients as anterior hypopituitarism. At follow-up visual deficits improved in 12 cases, headache resolved in 5, and ophthalmoplegia regressed in 2 cases. No improvement of the endocrinological function was observed. The mean survival was of 11.8 months (range, 3–43 months), three patients are still alive after 3.6 and 33 months, respectively, since the surgery. Conclusion: The diagnosis of a pituitary metastasis can be done only by histological examinations. In some cases, some clinical signs, such as DI and ophthalmoplegia, which are rarely present in benign sellar tumors, can orientate the suspect toward this diagnosis. Also, neuroimaging can be sometimes relevant, showing infiltrating, irregular tumors with thickening of the pituitary stalk. We observed two scenarios. In the first, all these clinical and neuroradiological signs were not present, and no malignant disease was known, thus the diagnosis of metastatic lesion could be unexpected during the surgery. In these cases, surgery permitted to obtain a diagnosis and to orientate the following oncologic stadiation. In the second, this diagnosis was suspected before surgery, but this has been considered indicated with the goal to improve or control the heavy and progressive debilitating symptoms of the patients, such as the visual worsening. Because the poor prognosis observed in the series, we conclude that surgery should be performed only in the presence of symptoms affecting the QOL, or in the absence of a systemic known malignant disease. The endoscopic transsphenoidal approach represents a minimally invasive approach and should be preferred in such compromised patients. The surgery resulted effective on the quality of life, but not on its expectancy.
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A055
What have been Changing in Craniopharyngiomas Surgery
Introduction: In the past 15 years, the endoscopic endonasal technique has been expanding its role in the surgery of craniopharyngiomas (CRph), allowing to treat not only endo- and suprasellar CRph, but also purely suprasellar tumors. We revised our surgical experience to investigate what has been changing in the choice of the surgical treatment, reporting out results with the innovative surgical approach. Materials and Methods: We retrospectively revised all midline craniopharyngiomas, treated between 1998 and 2012 through a transcranial and endoscopic endonasal approach at our center. All pre- and postoperative clinical reports and neuroimaging studies have been revised. Results: A total of 95 patients were operated through 126 surgical procedures. Of these patients, 26 were pediatrics. Overall, 65 patients had been operated through an EEA and 37 through a TA (seven cases had undergone to both surgeries). In the considered time, the endoscopic endonasal approach has progressively been becoming the approach of choice for all midline craniopharyngiomas, with the exception of the intraventricular tumors. The endoscopic endonasal approach has allowed to obtain a radical tumor removal in 84% of cases. Visual symptoms were normalized at follow-up in 34%, improved in 43%, and worsened in 3% (two cases). At endocrinological follow-up, 81% of patients presented panhypopituitarism, 17% partial hypopituitarism, and DI was present in 86% of cases. Quality of life is normal and was preserved in 86%. The recurrence rate was 11%. Complications consisted in 11 CSF leaks (17%), 2 (3%) hydrocephalus (one resulted fatal), and 1 chronic subdural hematoma (1.5%). Conclusion: During the past 15 years, endoscopic endonasal approach had proved an increasing role, becoming the treatment of choice for every CRphs, except the intraventricular tumors. This was because of the good visual outcome, the reduced neurological sequelae and the greater preservation of quality of life, which we observed with this approach. The endonasal route favors the dissection of the tumor though an arachnoid plane, allowing the preservation of nerves and vessels. Unfortunately, the EEA is hampered by a high complication rate, mainly represented by CSF leaks.
- 18 February 2015
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 76 (S 01) , A055
What have been Changing in Craniopharyngiomas Surgery
Introduction: In the past 15 years, the endoscopic endonasal technique has been expanding its role in the surgery of craniopharyngiomas (CRph), allowing to treat not only endo- and suprasellar CRph, but also purely suprasellar tumors. We revised our surgical experience to investigate what has been changing in the choice of the surgical treatment, reporting out results with the innovative surgical approach. Materials and Methods: We retrospectively revised all midline craniopharyngiomas, treated between 1998 and 2012 through a transcranial and endoscopic endonasal approach at our center. All pre- and postoperative clinical reports and neuroimaging studies have been revised. Results: A total of 95 patients were operated through 126 surgical procedures. Of these patients, 26 were pediatrics. Overall, 65 patients had been operated through an EEA and 37 through a TA (seven cases had undergone to both surgeries). In the considered time, the endoscopic endonasal approach has progressively been becoming the approach of choice for all midline craniopharyngiomas, with the exception of the intraventricular tumors. The endoscopic endonasal approach has allowed to obtain a radical tumor removal in 84% of cases. Visual symptoms were normalized at follow-up in 34%, improved in 43%, and worsened in 3% (two cases). At endocrinological follow-up, 81% of patients presented panhypopituitarism, 17% partial hypopituitarism, and DI was present in 86% of cases. Quality of life is normal and was preserved in 86%. The recurrence rate was 11%. Complications consisted in 11 CSF leaks (17%), 2 (3%) hydrocephalus (one resulted fatal), and 1 chronic subdural hematoma (1.5%). Conclusion: During the past 15 years, endoscopic endonasal approach had proved an increasing role, becoming the treatment of choice for every CRphs, except the intraventricular tumors. This was because of the good visual outcome, the reduced neurological sequelae and the greater preservation of quality of life, which we observed with this approach. The endonasal route favors the dissection of the tumor though an arachnoid plane, allowing the preservation of nerves and vessels. Unfortunately, the EEA is hampered by a high complication rate, mainly represented by CSF leaks.
- 1 April 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (4) , e45-e46
Prevalence and in-hospital mortality of hyponatremia: A cohort study
- 1 April 2014
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 25 (4) , e45-e46
Prevalence and in-hospital mortality of hyponatremia: A cohort study
- Open Access
- 7 March 2013
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (3) , 156-168
The hyponatremias
Introduction: Plasma sodium concentrations are commonly measured in hospitalized patients. In our department, hypernatremia (defined as a serum sodium < 135 mmol/L) is usually an incidental finding. More rarely, however, clinical manifestations of hypernatremia occur. Symptoms depend on the magnitude and rapidity of onset of the hypernatremia. When acute, severe hyponatremia develops, brain edema may occur. Considerable morbidity and mortality can be associated with hyponatremic encephalopathy per se. Moreover, rapid correction of hyponatremia also carries a risk of neurological damage related to the osmotic demyelination syndromes. This review focuses on the epidemiology, pathophysiology, and therapy of hyponatremia. Materials and methods: We carried out a search of the literature in Medline, the Cochrane Library and Clinical Evidence using the search terms hypernatremia and sodium. Conclusions: Hyponatremia is the most common electrolyte disorder encountered in clinical practice, occurring in approximately 15% to 30% of hospitalized patients, and it is not uncommon in outpatients. When faced with a hyponatremic patient, the physician has to identify the cause, treat the defect, and take care of the patient, bearing in mind that hypernatremia and its correction are associated with significant morbidity and mortality. Hyponatremic encephalopathy following acute hypernatremia is well known to be a potentially life-threatening condition, especially in patients with concomitant diseases. In contrast, chronic hypernatremia is more common, and it is often considered to be a laboratory abnormality devoid of clinical consequences. Paradoxically, however, this is just the setting in which rapid correction of plasma sodium levels can cause severe neurologic defects and death. Despite substantial progress in understanding the pathophysiology of brain damage related to hyponatremia and its treatment, optimal, safe therapies have not been well defined yet. The imminent availability of aquaretic nonpeptide arginine vasopressin receptor antagonists could provide new insights into this field. However, because of their unique effects, i.e., selective increase of solute-free water excretion by the kidney, this new class of drugs cannot be used in patients with hypovolemic hyponatremia.
- 7 March 2013
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (3) , 156-168
Open AccessThe hyponatremias
Introduction: Plasma sodium concentrations are commonly measured in hospitalized patients. In our department, hypernatremia (defined as a serum sodium < 135 mmol/L) is usually an incidental finding. More rarely, however, clinical manifestations of hypernatremia occur. Symptoms depend on the magnitude and rapidity of onset of the hypernatremia. When acute, severe hyponatremia develops, brain edema may occur. Considerable morbidity and mortality can be associated with hyponatremic encephalopathy per se. Moreover, rapid correction of hyponatremia also carries a risk of neurological damage related to the osmotic demyelination syndromes. This review focuses on the epidemiology, pathophysiology, and therapy of hyponatremia. Materials and methods: We carried out a search of the literature in Medline, the Cochrane Library and Clinical Evidence using the search terms hypernatremia and sodium. Conclusions: Hyponatremia is the most common electrolyte disorder encountered in clinical practice, occurring in approximately 15% to 30% of hospitalized patients, and it is not uncommon in outpatients. When faced with a hyponatremic patient, the physician has to identify the cause, treat the defect, and take care of the patient, bearing in mind that hypernatremia and its correction are associated with significant morbidity and mortality. Hyponatremic encephalopathy following acute hypernatremia is well known to be a potentially life-threatening condition, especially in patients with concomitant diseases. In contrast, chronic hypernatremia is more common, and it is often considered to be a laboratory abnormality devoid of clinical consequences. Paradoxically, however, this is just the setting in which rapid correction of plasma sodium levels can cause severe neurologic defects and death. Despite substantial progress in understanding the pathophysiology of brain damage related to hyponatremia and its treatment, optimal, safe therapies have not been well defined yet. The imminent availability of aquaretic nonpeptide arginine vasopressin receptor antagonists could provide new insights into this field. However, because of their unique effects, i.e., selective increase of solute-free water excretion by the kidney, this new class of drugs cannot be used in patients with hypovolemic hyponatremia.
- 1 May 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (5) , 1418-1419
Tuberculum Sellae Meningioma Growing during Pregnancy: A Difficult Decision-Making Process
- 1 May 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (5) , 1418-1419
Tuberculum Sellae Meningioma Growing during Pregnancy: A Difficult Decision-Making Process
- Open Access
- 2 January 2012
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (4)
Erratum a: Le iponatremie [Italian Journal of Medicine 2011;5(3):156-68.]
- 2 January 2012
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (4)
Open AccessErratum a: Le iponatremie [Italian Journal of Medicine 2011;5(3):156-68.]
- 1 December 2011
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (4) , 288
Erratum a: Le iponatremie [Italian Journal of Medicine 2011;5(3):156-68.]
- 1 December 2011
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 5 (4) , 288
Erratum a: Le iponatremie [Italian Journal of Medicine 2011;5(3):156-68.]